- AeroSafe Global recently announced that Peloton Equity, LLC invested $31.5 million into the company
AeroSafe Global recently announced that Peloton Equity, LLC — accounts managed by Hamilton Lane — and certain existing investors such as Flexstone Partners have invested an aggregate of $31.5 million of growth capital in the company. And AeroSafe will use the funding for accelerating sales and marketing efforts, launching additional value-added services and technologies, and expanding into new geographies.
With over 30 Fortune 500 pharmaceutical and healthcare customers, AeroSafe is the principal provider of outsourced cold-chain-as-a-service (CCaaS) solutions for the pharmaceutical, biopharmaceutical, and medical device industries. And AeroSafe’s innovative packaging technology, cost-efficient re-use business model, and data tracking and analytics ensure the efficient and sustainable delivery of temperature-sensitive drugs and devices while providing customers with a streamlined solution for the entire cold chain from manufacturer to end-user.
“Peloton’s expertise and network in the healthcare segment will bring additional resources, insights and business development opportunities to accelerate industry adoption of AeroSafe’s innovative products and technologies,” said AeroSafe CEO Jay McHarg. “This new financing round expands our team of blue-chip investors who enthusiastically support AeroSafe’s growth plans.”
The global biopharmaceutical cold chain logistics market (currently estimated at $15 billion) is growing rapidly due to advancements in biologics, vaccines, cell therapy products, and other drugs and devices that are manufactured to temperature specificity and require maintenance of that temperature range throughout the supply chain.
“The market AeroSafe serves is massive and is becoming an increasingly important component of the global pharma supply chain. Peloton has been looking for differentiated growth companies in this space for a long time, and we are particularly impressed with AeroSafe’s re-use business model, product technology and customer service performance,” added Justin Yang — a partner at Peloton Equity. “We are very excited to partner with Jay and his team in supporting AeroSafe’s next phase of growth.”
The drugs and devices are often for the treatment of chronic conditions and life-threatening illnesses. And in many cases, it represents pharmaceutical and device manufacturers’ most critical products. AeroSafe’s track record of temperature reliability across a range of shipping situations has been appreciated by many customers.
“Our transformation from a product company to a leading-edge, technology-based service company has enabled us to become a partner, rather than a vendor, to our customers,” added McHarg. “This investment will allow AeroSafe to continue to innovate to meet the market’s evolving cold chain needs. We see a bright future for our customers, investors and team members.”
Peloton co-founding partner Ted Lundberg is joining Justin Yang on the board of directors. Peloton is the successor firm to Ferrer Freeman & Company (FFC) and the team has over 60 years of combined healthcare investing experience.
